Published in Best Pract Res Clin Endocrinol Metab on October 01, 2008
Cost of falls in old age: a systematic review. Osteoporos Int (2009) 2.03
Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int (2011) 0.99
Health technology assessment in osteoporosis. Calcif Tissue Int (2013) 0.85
Osteoporosis in the community: Sensitivity of self-reported estimates and medication use of those diagnosed with the condition. Bone Joint Res (2012) 0.82
Cost-effectiveness of a multifactorial fall prevention program in nursing homes. Osteoporos Int (2012) 0.79
Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporos Int (2009) 0.78
Access to oral osteoporosis drugs among female Medicare Part D beneficiaries. Womens Health Issues (2014) 0.75
Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis. Osteoporos Int (2013) 0.75
Does the frequency and intensity of physical activity in adolescence have an impact on bone? The Tromsø Study, Fit Futures. BMC Sports Sci Med Rehabil (2015) 0.75
Predictive value of BMD for hip and other fractures. J Bone Miner Res (2005) 6.46
Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (2013) 5.93
Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol (2002) 3.01
The cost-effectiveness of alendronate in the management of osteoporosis. Bone (2007) 2.75
Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Miner Res (2012) 2.22
Assessment of the 10-year probability of osteoporotic hip fracture combining clinical risk factors and heel bone ultrasound: the EPISEM prospective cohort of 12,958 elderly women. J Bone Miner Res (2008) 2.20
Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos (2011) 2.14
Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res (2010) 1.90
Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res (2014) 1.86
FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res (2012) 1.82
Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res (2012) 1.77
Vertebral fracture assessment (VFA) with a densitometer predicts future fractures in elderly women unselected for osteoporosis. J Bone Miner Res (2008) 1.69
The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approach. Osteoporos Int (2004) 1.60
A meta-analysis of the association of fracture risk and body mass index in women. J Bone Miner Res (2014) 1.56
Type 2 diabetes and bone. J Bone Miner Res (2012) 1.53
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis. Bone (2008) 1.48
Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res (2007) 1.45
Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res (2003) 1.39
Risk factors for incident vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res (2004) 1.27
Incidence rates and life-time risk of hip fractures in Mexicans over 50 years of age: a population-based study. Osteoporos Int (2005) 1.23
Cortical porosity identifies women with osteopenia at increased risk for forearm fractures. J Bone Miner Res (2014) 1.21
Quality of life in sarcopenia and frailty. Calcif Tissue Int (2013) 1.17
Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res (2004) 1.16
Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res (2004) 1.14
Milk intake and risk of hip fracture in men and women: a meta-analysis of prospective cohort studies. J Bone Miner Res (2011) 1.11
International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med (2011) 1.10
Optimization of BMD measurements to identify high risk groups for treatment--a test analysis. J Bone Miner Res (2004) 1.05
Adjusting fracture probability by trabecular bone score. Calcif Tissue Int (2015) 1.04
Evidence from data searches and life-table analyses for gender-related differences in absolute risk of hip fracture after Colles' or spine fracture: Colles' fracture as an early and sensitive marker of skeletal fragility in white men. J Bone Miner Res (2004) 1.02
Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice. J Clin Densitom (2011) 1.00
Health economics in the field of osteoarthritis: an expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum (2013) 0.95
Incidence of hip fracture in Romania and the development of a Romanian FRAX model. Calcif Tissue Int (2013) 0.93
Fracture risk assessment. Clin Biochem (2012) 0.93
Inflammatory bowel disease and the risk of fracture after controlling for FRAX. J Bone Miner Res (2013) 0.93
High serum adiponectin predicts incident fractures in elderly men: Osteoporotic fractures in men (MrOS) Sweden. J Bone Miner Res (2012) 0.92
A meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif Tissue Int (2014) 0.91
Potential impact of osteoporosis treatment on hip fracture trends. J Bone Miner Res (2005) 0.91
The effect of latitude on the risk and seasonal variation in hip fracture in Sweden. J Bone Miner Res (2014) 0.90
FRAX updates 2012. Curr Opin Rheumatol (2012) 0.90
Smoking predicts incident fractures in elderly men: Mr OS Sweden. J Bone Miner Res (2010) 0.88
From relative risk to absolute fracture risk calculation: the FRAX algorithm. Curr Osteoporos Rep (2009) 0.88
Assessing the impact of osteoporosis on the burden of hip fractures. Calcif Tissue Int (2012) 0.88
Epidemiology of fracture in the Russian Federation and the development of a FRAX model. Arch Osteoporos (2012) 0.87
A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. Pharmacoeconomics (2015) 0.87
Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: estimations from a disease model. Arch Osteoporos (2011) 0.86
How to define responders in osteoarthritis. Curr Med Res Opin (2013) 0.86
Health technology assessment in osteoporosis. Calcif Tissue Int (2013) 0.85
Hip axis length is a FRAX- and bone density-independent risk factor for hip fracture in women. J Clin Endocrinol Metab (2015) 0.84
European guidance for the diagnosis and management of osteoporosis in postmenopausal women--what is the current message for clinical practice? Pol Arch Med Wewn (2008) 0.84
Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics (2004) 0.84
Official Positions for FRAX® Bone Mineral Density and FRAX® simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom (2011) 0.84
Can change in FRAX score be used to "treat to target"? A population‐based cohort study. J Bone Miner Res (2014) 0.82
Estimated lean mass and fat mass differentially affect femoral bone density and strength index but are not FRAX independent risk factors for fracture. J Bone Miner Res (2014) 0.82
The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks. Value Health (2007) 0.82
Critical issues in translational and clinical research for the study of new technologies to enhance bone repair. J Bone Joint Surg Am (2008) 0.82
FRAX updates 2016. Curr Opin Rheumatol (2016) 0.82
Cost-effectiveness of hormone therapy in the United States. J Womens Health (Larchmt) (2009) 0.81
Selection of women aged 50-64 yr for bone density measurement. J Clin Densitom (2013) 0.80
Hip fracture incidence from 1981 to 2009 in the Czech Republic as a basis of the country-specific FRAX model. Calcif Tissue Int (2012) 0.79
Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty. Drugs Aging (2015) 0.78
Potential Extensions of the US FRAX Algorithm. J Osteoporos (2012) 0.78
FRAX-based intervention and assessment thresholds for osteoporosis in Romania. Arch Osteoporos (2013) 0.78
The application of FRAX® to determine intervention thresholds in osteoporosis treatment in Poland. Pol Arch Med Wewn (2011) 0.77
The impact of a FRAX-based intervention threshold in Turkey: the FRAX-TURK study. Arch Osteoporos (2012) 0.76
FRAX(®) Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. J Clin Densitom (2011) 0.76
Development and application of FRAX in the management of osteoporosis in Ireland. Arch Osteoporos (2013) 0.75
[FRAX--model for 10-year fracture risk assessment. Support in the treatment of osteoporosis, according to preliminary Swedish guidelines]. Lakartidningen (2011) 0.75
Standardising biochemical assessment of bone turnover in osteoporosis. Clin Biochem (2011) 0.75
Recommendations for bone marker standards in osteoporosis: what, why and where to now? Ann Clin Biochem (2011) 0.75
Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK. Menopause Int (2009) 0.75
Herbert Andre Fleisch, MD : 22 July 1933-15 May 2007. Osteoporos Int (2007) 0.75